GLP-1 Drugs and Male Fertility: Could Weight-Loss Treatment Help Sperm?

GLP-1 drugs and male fertility are drawing interest after research presented at ENDO 2026. A review of small randomized trials reported improvements in some hormonal and semen outcomes in men with obesity and low testosterone. Whether these changes translate into more live births remains unanswered.

Research presented at ENDO 2026 suggests that metabolic treatment may influence some male reproductive markers. That is a promising question, not yet proof that GLP-1 medicines treat infertility successfully.

Obesity and reproductive health

Obesity can be associated with lower testosterone and altered semen parameters through several pathways. Not all men with obesity have impaired fertility, and metabolic health does not explain every male-factor diagnosis.

The “Paradox” of Current Hormone Treatments

For years, the standard clinical response to low testosterone has been hormone replacement therapy (HRT). However, for men planning to start a family, HRT is often counterproductive. Exogenous testosterone signals the brain to shut down natural production, effectively suppressing the body’s own spermatogenesis. In fact, many young men who misuse anabolic steroids or testosterone for performance enhancement end up in clinics with profound, and sometimes near-total, suppression of sperm production.

A different therapeutic question

GLP-1 medicines treat approved metabolic indications. Researchers are investigating associated changes in reproductive hormones and semen parameters:

Metabolic effects: Weight and glucose changes may accompany reproductive changes, but mechanisms and responders need further study.
Hormonal measures: Testosterone changes are not equivalent to restored fertility.
Semen outcomes: Some trial findings were encouraging; more sperm or a better parameter does not itself establish more live births.

A Note of Clinical Caution

While the potential is significant, it is premature to classify Wegovy or Mounjaro as “fertility drugs.” The studies are still in their infancy, with small sample sizes and relatively short follow-up periods. Crucially, we have yet to confirm whether these improvements directly translate into higher rates of live births. Experts emphasize that more clinical trials are needed before these drugs can be considered a standard treatment for male infertility.

Broader health without a single-cause story

Male infertility can coexist with metabolic disease, but it can also arise from genetic, anatomical and other causes. Assessment should remain broad.

Future trials need to determine who benefits, how durable any change is and whether reproductive outcomes improve. Metabolic treatment may complement fertility care; it should not be advertised as a replacement for established evaluation.

Disclaimer: This report is for informational purposes. The use of GLP-1 weight-loss medications should only be conducted under the supervision of a medical professional, and their safety during pregnancy planning requires careful clinical consideration.

What was reported—and what remains unknown

The University Hospitals Coventry and Warwickshire/Warwick Medical School researchers reviewed randomized trials for the ENDO 2026 presentation. The reported hormonal and semen changes need confirmation in larger studies with reproductive outcomes. Endocrine Society: ENDO 2026 research report.